In partnership with Intel-GE Care Innovations, Cigna-HealthSpring is expanding its population health program that utilizes interactive tablets – the Intel-GE Care Innovations Guide – and virtual connection to Cigna-HealthSpring nurse practitioners to partner and engage with patients diagnosed with congestive heart failure (CHF) to successfully manage their condition at home. Based on a successful pilot in Middle Tennessee that engaged 50 patients, the innovative remote patient management program is now being implemented with 250 patients statewide with potential for further expansion.

Researchers have discovered a previously unknown cardiac molecule that could provide a key to treating and preventing heart failure. The newly discovered molecule provides the heart with a tool to block a protein that orchestrates genetic disruptions when the heart is subjected to stress, such as high blood pressure.

Although the highly saturated picture archiving and communication systems (PACS) segment is slowing growth in the U.S. imaging informatics market, a few niche areas are advancing forming new growth areas. 

The U.S. Food and Drug Administration (FDA) approved Lumason (sulfur hexafluoride lipid microsphere) for patients whose ultrasound image of the heart (echocardiograms) are hard to see with ultrasound waves.

Infraredx Inc. announced that its dual-modality intravascular imaging technology, TVC Imaging System, and its TVC Insight Catheter received Shonin approval from the Japanese Ministry of Health, Labour and Welfare (MHLW).

Presented for the first time at the 2014 Transcatheter Cardiovascular Therapeutics (TCT) conference, the latest clinical and economic data on the IN.PACT Admiral drug-coated balloon (DCB) from Medtronic Inc. augments an already robust body of evidence that continues to drive a reconsideration of the standard of care for peripheral artery disease (PAD) in leg arteries above the knee.

Covidien announced that it has notified customers of a voluntary Field Safety Alert for certain Medi-Trace Cadence and Kendall Multi-function Defibrillation Electrodes due to a connector compatibility issue with Philips FR3 and FRx defibrillators.

October 13, 2014 — After reviewing updated data and analysis for the Boston Scientific Watchman left atrial appendage (LAA) closure device, the U.S. Food and Drug Administration (FDA) Circulatory System Devices Panel of the Medical Devices Advisory Committee voted in favor of the device. By a vote of 6 to 5 (with 1 abstention) the panel concluded the benefits of the Watchman device outweigh the potential risks.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now